BioSpace News Archive

Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, today announced that enrollment is complete in the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study. CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics

Company Completed 30 Acquisitions In 2019 Representing 60 Practices Acuity Also Announces Strategic Rebranding As AEG Vision

Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation reviewing the Company’s two Phase 3 clinical programs and pipeline at the 22nd Annual BIO CEO & Investor Conference in New York Cit

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the amount of $3.9 million to support development of TLY012 for treatment of chronic pancreatitis.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2019 update and financial results on Thursday, February 13 at 8:30 a.m. ET.

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the achievement of clinical development milestones for two of its exclusively-licensed, clinical-stage products to Boehringer Ingelheim (BI) and Bristol-Myers Squibb Company (BMS) (NYSE:BMY).

NeoImmuneTech, Inc., a T cell-focused immunotherapeutics company, today announced the appointment of Gene Namgoong as Chief Operating Officer (COO).

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced that it has implemented new quality assurance management and production procedures at Prodigy Textiles, the Company’s Vietnamese subsidiary, based on lessons learned from its production rollout.

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for FS120, F-star’s proprietary tetravalent bispecific antibody targeting CD137 and OX40.